| Basics |
Gilead Sciences, Inc.
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$142.75B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.73 | 1.13%
|
| Avg Daily Range (30 D): |
$0.91 | 0.80%
|
| Avg Daily Range (90 D): |
$1.24 | 1.15%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
7.34M |
| Avg Daily Volume (30 D): |
4.53M |
| Avg Daily Volume (90 D): |
5.39M |
| Trade Size |
| Avg Trade Size (Sh.): |
139 |
| Avg Trade Size (Sh.) (30 D): |
58 |
| Avg Trade Size (Sh.) (90 D): |
64 |
| Institutional Trades |
| Total Inst.Trades: |
120,967 |
| Avg Inst. Trade: |
$5.21M |
| Avg Inst. Trade (30 D): |
$14.45M |
| Avg Inst. Trade (90 D): |
$14.21M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
21 |
| Market Closing Trades |
| Avg Closing Trade: |
$54.7M |
| Avg Closing Trade (30 D): |
$115.34M |
| Avg Closing Trade (90 D): |
$141.32M |
| Avg Closing Volume: |
841.1K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$5.05
|
$1.57
|
$1.06
|
|
Diluted EPS
|
$5.03
|
$1.56
|
$1.04
|
|
Revenue
|
$ 28.86B
|
$ 7.08B
|
$ 6.67B
|
|
Gross Profit
|
$ 22.67B
|
$ 5.58B
|
$ 5.13B
|
|
Net Income / Loss
|
$ 6.31B
|
$ 1.96B
|
$ 1.32B
|
|
Operating Income / Loss
|
$ 8.05B
|
$ 2.47B
|
$ 2.24B
|
|
Cost of Revenue
|
$ 6.2B
|
$ 1.5B
|
$ 1.54B
|
|
Net Cash Flow
|
$ 2.37B
|
$ -2783M
|
$ -2065M
|
|
PE Ratio
|
22.88
|
|
|
| Splits |
|
Jan 28, 2013:
2:1
|
|
Jun 25, 2007:
2:1
|
|
Sep 07, 2004:
2:1
|
|
Mar 08, 2002:
2:1
|
|
Feb 22, 2001:
2:1
|
|
|
|
